Dna hypermethylation of tumor suppressor genes rassf6 and rassf10 in adult acute lymphoblastic leukemia: methylation status of rassf6 is a poor prognostic biomarker in pre-b all

The DNA hypermethylation in the CpG island promoter of tumor suppressor genes are an epigenetic modification observed in acute lymphoblastic leukemia (ALL) and has been found to be correlated withpoor prognosis and increased rates of relapse. Hypermethylation of Ras association domain family (RASSF) often plays a key role in malignant progression of solid tumors; however, their impact on theprognosis and survival of adult ALL patients remain elusive. The frequency of the promoter methylation pattern of RASSF6 and RASSF10 were analyzed in the peripheral blood (PB) samples taken at the time of diagnosis of 45 ALL patients. The methylation-specific PCR (MSP) assay was used to detect the DNA methylation patterns. RASSF6 was frequently hypermethylated in patients diagnosed with pre-B-ALL (90.9%) and B-ALL (87.5%), followed by T-ALL (66.7%); whereas, RASSF10 methylation was more confined to T-ALL (80%) as compared to B-ALL (25%) and pre-B ALL (9.1%) patients. Moreover, hypermethylation of RASSF6 was significantly associated with a poor prognosis and shorter overall survival (OS) in patients with pre-B-ALL (log-rank test; P = 0.041). RASSF6 and RASSF10 were frequently hypermethylated in the samples at the time of diagnosis of adult ALL patients. Our study represents the first report of methylation of RASSF6 at a high frequency in patients with pre-B ALL. Furthermore, hypermethylation of RASSF6 was significantly associated with inferior overall survival in pre-B ALL patients. It may suggest that the frequent epigenetic inactivation of RASSF6 plays an important role in the pathogenesis and progression of pre-B-ALL.

کلیدواژه ها:

Blood Cancer ، Cancer Diagnosis ، Cancer Risks ، Cancer Genetics ، Cancer Treatment and Management